In contrast to our results with ribociclib, it has been reported that abemaciclib, a CDK4/6 inhibitor, did not significantly alter the expression of the P-gp transporter in cancer cells overexpressing the P-gp transporter (Wu et al., 2017). This evidence concerns the gene CDK4 and cancer.